Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uri Kopylov

Showing results (1-10 of 284) with videos related to

Pageof 29
Sort By:
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Author's replyUri Kopylov
Alimentary Pharmacology & Therapeutics|August 28, 2020
Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's replyUri Kopylov
The Lancet. Gastroenterology & Hepatology|November 8, 2025
Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopyAsaf Levartovsky, Uri Kopylov
Annals of Gastroenterology|July 2, 2016
Advances in the development of new biologics in inflammatory bowel diseaseBella Ungar, Uri Kopylov
Journal of Clinical Medicine|August 12, 2022
Comprehensive Management of Inflammatory Bowel Disease: What's NextAsaf Levartovsky, Uri Kopylov
Alimentary Pharmacology & Therapeutics|April 15, 2020
Editorial: is vedolizumab effective for perianal Crohn's disease?Bella Ungar, Uri Kopylov
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 20, 2026
Author's reply: "A critical re-evaluation of the VEDUST-EXIT study: Beyond the headline relapse rate"Ahmad Albshesh, Uri Kopylov
Gastroenterology Clinics of North America|August 12, 2014
Risk of infections with biological agentsUri Kopylov, Waqqas Afif
Journal of Crohn'S & Colitis|November 1, 2016
The Lemann Index-A Glance Through the Window of Opportunity?Uri Kopylov, Rami Eliakim
United European Gastroenterology Journal|August 4, 2020
Long-term outcome of ulcerative proctitisBella Ungar, Uri Kopylov
Pageof 29

Showing results (1-10 of 284) with videos related to

Sort By:
Pageof 29
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Author's replyUri Kopylov
Alimentary Pharmacology & Therapeutics|August 28, 2020
Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's replyUri Kopylov
The Lancet. Gastroenterology & Hepatology|November 8, 2025
Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopyAsaf Levartovsky, Uri Kopylov
Annals of Gastroenterology|July 2, 2016
Advances in the development of new biologics in inflammatory bowel diseaseBella Ungar, Uri Kopylov
Journal of Clinical Medicine|August 12, 2022
Comprehensive Management of Inflammatory Bowel Disease: What's NextAsaf Levartovsky, Uri Kopylov
Alimentary Pharmacology & Therapeutics|April 15, 2020
Editorial: is vedolizumab effective for perianal Crohn's disease?Bella Ungar, Uri Kopylov
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 20, 2026
Author's reply: "A critical re-evaluation of the VEDUST-EXIT study: Beyond the headline relapse rate"Ahmad Albshesh, Uri Kopylov
Gastroenterology Clinics of North America|August 12, 2014
Risk of infections with biological agentsUri Kopylov, Waqqas Afif
Journal of Crohn'S & Colitis|November 1, 2016
The Lemann Index-A Glance Through the Window of Opportunity?Uri Kopylov, Rami Eliakim
United European Gastroenterology Journal|August 4, 2020
Long-term outcome of ulcerative proctitisBella Ungar, Uri Kopylov
Pageof 29